All In Biotech

Drug Trial Radar · NCT06336603

A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Adapalene 0.3% for the Treatment of Acne

The Combination Use of Winlevi and Adapalene 0.3% Gel in Real Life Acne Treatment

Last checked: Nov 20, 2026Latest source record: Oct 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

20

Actual

Start

Nov 15, 2023

Primary completion

Oct 29, 2024

Study completion Oct 29, 2024

Sponsor

Sponsor type
Industry
First posted
Mar 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Winlevi is the first topical anti androgen and sebum inhibitor approved for acne vulgaris. There is no study assessing Winlevi in combination treatment for acne .Therefore this study assesses Winlevi with Adapalene 0.3% gel in combination to emulate real life practice.

Conditions

  • Acne Vulgaris

Interventions

  • Winlevi (clascoterone) 1% & Adapalene 0.3% gelDrug

    Participants will use Winlevi (clascoterone) 1% twice daily (BID) and Adapalene 0.3% once daily (QD)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Primary Endpoint of This Study is the Percent of Patients Who Achieve Clear or Almost Clear on IGA at Week 16.Time frame: Week 16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Skin Sciences, PLLC

    Louisville, Kentucky

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.